EpiCast Report: Non-Small Cell Lung Cancer (NSCLC) - Epidemiology Forecast to 2025 - Product Image

EpiCast Report: Non-Small Cell Lung Cancer (NSCLC) - Epidemiology Forecast to 2025

  • ID: 3993799
  • Drug Pipelines
  • 67 pages
  • GlobalData
1 of 3
Lung cancer is a disease of uncontrolled cell growth in the lung tissues. It is one of the most commonly occurring cancers in the world (IARC, 2016). Lung cancer is classified into three main types: non-small cell lung cancer (NSCLC), small cell lung cancer, and lung carcinoid tumor. NSCLC is the most common type of lung cancer, making up about 85% of all lung cancers. Small cell lung cancer accounts for 10-15% of lung cancers, while carcinoid tumors are the rarest, occurring in fewer than 5% of lung cancers (ACS, 2016).

In the 8MM, the diagnosed incident cases of NSCLC will increase from 791,563 cases in 2015 to 1,069,516 cases in 2025, at an Annual Growth Rate (AGR) of 3.51% per year. In the five major European markets (5EU: France, Germany, Italy, Spain, and the UK), the diagnosed incident cases of NSCLC will increase from 172,998 cases in 2015 to 194,435 cases in 2025, at an AGR of 1.24%.

In 2015, there were 1,199,845 five-year diagnosed prevalent cases of NSCLC in the 8MM, which is expected to increase to 1,626,132 cases by 2025, at an AGR of 3.55%. Among the 8MM, China had the highest number of five-year diagnosed prevalent cases of NSCLC in 2015 and 2025, at 439,438 cases and 708,530 cases, respectively, and will have the highest growth in the 8MM at an AGR of 6.12%.

The relative survival of NSCLC varies by subtype, where adenocarcinoma has the highest survival, followed by squamous cell carcinoma, and large cell carcinoma. In the alternate forecast, due to the forecast increase in adenocarcinoma during 2015-2025, epidemiologists expect an increase in relative survival and, consequently, an increase in the number of five-year diagnosed prevalent cases of NSCLC.

The report “EpiCast Report: Non-Small Cell Lung Cancer (NSCLC) - Epidemiology Forecast to 2025” provides an overview of the risk factors and the global and historical trends for NSCLC in the eight major markets (8MM): US, France, Germany, Italy, Spain, UK, Japan, China (urban). It also includes a 10-year epidemiology forecast of the diagnosed incident and five-year diagnosed prevalent cases of NSCLC in these markets from 2015-2025.

The incident cases are further segmented by sex and age (18-39 years, 40-59 years, 60-79 years, and 80 years and older), cancer stage at diagnosis (IA, IB, IIA, IIB, IIIA, IIIB, and IV), cancer histology subtype (adenocarcinoma, squamous cell carcinoma, large cell carcinoma, and other). Moreover, this report provides an alternate forecast scenario that takes into account potential changes in the diagnosed incident cases distribution by histology subtype. The alternate forecast also examines the impact of potential changes in histology subtypes on the 10-year epidemiology forecast of the five-year prevalent cases of NSCLC from 2015-2025.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1.1 List of Tables

1.2 List of Figures

2 Epidemiology

2.1 Disease Background

2.2 Risk Factors and Comorbidities

2.3 Global Trends

2.3.1 Incidence

2.3.2 Histological Subtypes

2.3.3 Relative Survival

2.4 Forecast Methodology

2.4.1 Sources Used

2.4.2 Forecast Assumptions and Methods - Base Forecast

2.4.3 Forecast Assumptions and Methods - Alternate Forecast

2.4.4 Sources Not Used

2.5 Epidemiological Forecast for NSCLC (2015-2025) - Base Forecast

2.5.1 Diagnosed Incident Cases of NSCLC

2.5.2 Age-Specific Diagnosed Incident Cases of NSCLC

2.5.3 Sex-Specific Diagnosed Incident Cases of NSCLC

2.5.4 Age-Standardized Diagnosed Incidence of NSCLC

2.5.5 Diagnosed Incident Cases of NSCLC by Clinical Stage at Diagnosis

2.5.6 Diagnosed Incident Cases of NSCLC by Histology Subtype

2.5.7 Mutations Among Diagnosed Incident Cases of Adenocarcinoma

2.5.8 Mutations Among Diagnosed Incident Cases of Squamous Cell Carcinoma

2.5.9 Mutations Among Diagnosed Incident Cases of NSCLC

2.5.10 Five-Year Diagnosed Prevalent Cases of NSCLC

2.6 Epidemiological Forecast for NSCLC (2015-2025) - Alternate Forecast

2.6.1 Alternate Forecast - Diagnosed Incident Cases of NSCLC by Histology

2.6.2 Alternate Forecast - Five-Year Diagnosed Prevalent Cases of NSCLC

2.7 Discussion

2.7.1 Epidemiological Forecast Insight

2.7.2 Limitations of the Analysis

2.7.3 Strengths of the Analysis

3 Appendix

3.1 Bibliography

3.2 About the Authors

3.2.1 Epidemiologists

3.2.2 Reviewers

3.2.3 Global Director of Therapy Analysis and Epidemiology

3.3 About the Author

3.4 About EpiCast

3.5 Disclaimer

1.1 List of Tables

Table 1: Risk Factors and Comorbidities for Lung Cancer

Table 2: Histological Subtype Distribution Among NSCLC

Table 3: 8MM, Relative Survival

Table 4: 8MM, Sources Used for Diagnosed Incidence of NSCLC

Table 5: 8MM, Sources Used for Cancer Stage at Diagnosis

Table 6: 8MM, Sources Used for NSCLC by Histological Subtypes

Table 7: US, Sources Used for Diagnosed Incident Cases of NSCLC Segmented by Mutation

Table 8: 5EU, Sources Used for Diagnosed Incident Cases of NSCLC Segmented by Mutation

Table 9: Japan, Sources Used for Diagnosed Incident Cases of NSCLC Segmented by Mutation

Table 10: China (Urban), Sources Used for Diagnosed Incident Cases of NSCLC Segmented by Mutation

Table 11: 8MM, Sources Used for Relative Survival of NSCLC

Table 12: 8MM, Diagnosed Incident Cases of NSCLC, Both Sexes, Ages =18 Years, N, Select Years 2015-2025

Table 13: 8MM, Age-Specific Diagnosed Incident Cases of NSCLC, Both Sexes, N (Row %), 2015

Table 14: 8MM, Sex-Specific Diagnosed Incident Cases of NSCLC, Ages =18 Years, N (Row %), 2015

Table 15: 8MM, Diagnosed Incident Cases of NSCLC by Clinical Stage at Diagnosis, Ages =18 Years, N, 2015

Table 16: 8MM, Diagnosed Incident Cases of NSCLC by Histological Subtypes, Ages =18 Years, N, 2015

Table 17: 8MM, Mutations Among Diagnosed Incident Cases of Adenocarcinoma, Both Sexes, Ages =18 Years, N, 2015

Table 18: 8MM, Mutations Among Diagnosed Incident Cases of Squamous Cell Carcinoma, Both Sexes, Ages =18 Years, N, 2015

Table 19: 8MM, Mutations Among Diagnosed Incident Cases of NSCLC, Both Sexes, N, Ages =18 Years, 2015

Table 20: 8MM, Five-Year Diagnosed Prevalent Cases of NSCLC, Both Sexes, Ages =18 Years, N, Select Years 2015-2025

Table 21: 8MM, Alternate Forecast, Diagnosed Incident Cases of NSCLC by Histology Subtypes, Ages =18 Years, N, 2015 and 2025

Table 22: 8MM, Alternate Forecast, Five-Year Diagnosed Prevalent Cases of NSCLC, Both Sexes, Ages =18 Years, N, Select Years 2015-2025

1.2 List of Figures

Figure 1: 8MM, Diagnosed Incident Cases of NSCLC, Both Sexes, Ages =18 Years, N, Select Years 2015-2025

Figure 2: 8MM, Age-Specific Diagnosed Incident Cases of NSCLC, Both Sexes, N, 2015

Figure 3: 8MM, Sex-Specific Diagnosed Incident Cases of NSCLC, Ages =18 Years, N, 2015

Figure 4: 8MM, Age-Standardized Diagnosed Incidence of NSCLC, Ages =18 Years, N, 2015

Figure 5: 8MM, Five-Year Diagnosed Prevalent Cases of NSCLC, Both Sexes, Ages =18 Years, N, Select Years 2015-2025
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll